Funding
← Back to your selection

Canaan Partners

Activity from announced rounds

Activity in this selectionUnited States · Oct 16, 2026 · Jul 19, 2026
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$232M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Series A1

By primary sector

AI1
Biotech1

By country

United States2

Rounds

2 in this selection
Solstice Oncology

A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.

$225MSeries A
Participant
Actualyze AI

An enterprise gateway for AI-model access, request security, budgets and routing.

$7MSeed
Role not disclosed